1British Committee for standards in Haematology General Haematology Task Force.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults,children and in pregnancy[J].Br J Haematol,2003,120(4):574-596. 被引量：1
2McFarland J.Pathophysiology of platelet destruction in immune (idiopathic) thrombocytopenic purpura[J].Blood Rev,2002,16(1):1-2. 被引量：1
4Reff ME,Carner K,Chambers KS,et al.Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20[J].Blood,1994,83(2):435-444. 被引量：1
5Stanglmaier M,Reis S,Hallek M.Rituximab and alemtuzumab induce a nonclassic,caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphoid cell lines and in chronic lymphocytic leukemia cells[J].Ann Hematol,2004,83(10)634-645. 被引量：1
6Cooler N, Stasi R, Rundles S, et al. The efficacy and safety of B-ceU depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol,2004 ,125 (2) :232-239. 被引量：1
7Nagahama M, Nomura S, Kanazawa S, et al. Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocylopenic purpura. Ear J Haematol, 2002,69 ( 5- 6) :303-308. 被引量：1
8Kuwana M,Nomura S,Fujimura K,et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood,2004,103 (4) : 1229 -1236. 被引量：1
9Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20 Hodgkin's lymphoma with the monocleonal antibody rituximab is effective and well tolerated:result of a phase 2 trail of the German Hodgkin's lymphoma study Group[J]. Blood, 2003,101 (2) : 420. 被引量：1
10Hoehster HS,Weller E,Ryan T,et al. Results of E1496:a phase Ⅲ trial of CVP with or without maintenance rituximab in advanced indolent lymphoma(NHL) [J]. Proc Am Soc Clin Oncol,2004,22(14) :6502. 被引量：1
